Literature DB >> 9500957

Combined treatment of acute EAE in Lewis rats with TNF-binding protein and interleukin-1 receptor antagonist.

B Wiemann1, G Y Van, D M Danilenko, Q Yan, C Matheson, L Munyakazi, S Ogenstad, C O Starnes.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a term given to describe a collection of animal models representing the human disease multiple sclerosis (MS). Although not fully understood, the involvement of cytokines and the immune system in either EAE or human MS is well established. Past efforts have shown that inhibition of proinflammatory cytokines tumor necrosis factor (TNF-alpha) or interleukin-1 (IL-1) result in amelioration of acute EAE in Lewis rats. The present study examined this model for the effect of concomitant inhibition of both TNF-alpha and IL-1, which resulted in a modest but significant therapeutic effect that was superior to inhibition of either single agent alone with respect to four of the five variables used to follow the progression of disease in this model, i.e., clinical severity, frequency of disease, loss of body weight, and day of onset. These results are in accordance with the idea that combination treatments are likely to prove superior to single agent therapy in the treatment of autoimmune inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9500957     DOI: 10.1006/exnr.1997.6723

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  Immune modulation by chondroitin sulfate and its degraded disaccharide product in the development of an experimental model of multiple sclerosis.

Authors:  Juhua Zhou; Prakash Nagarkatti; Yin Zhong; Mitzi Nagarkatti
Journal:  J Neuroimmunol       Date:  2010-06       Impact factor: 3.478

Review 2.  New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.

Authors:  Chih-Chung Lin; Brian T Edelson
Journal:  J Immunol       Date:  2017-06-15       Impact factor: 5.422

3.  Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis.

Authors:  Georgia Mandolesi; Alessandra Musella; Antonietta Gentile; Giorgio Grasselli; Nabila Haji; Helena Sepman; Diego Fresegna; Silvia Bullitta; Francesca De Vito; Gabriele Musumeci; Claudio Di Sanza; Piergiorgio Strata; Diego Centonze
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

4.  Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.

Authors:  K Akassoglou; K W Kombrinck; J L Degen; S Strickland
Journal:  J Cell Biol       Date:  2000-05-29       Impact factor: 10.539

5.  Acid sphingomyelinase activity triggers microparticle release from glial cells.

Authors:  Fabio Bianco; Cristiana Perrotta; Luisa Novellino; Maura Francolini; Loredana Riganti; Elisabetta Menna; Laura Saglietti; Edward H Schuchman; Roberto Furlan; Emilio Clementi; Michela Matteoli; Claudia Verderio
Journal:  EMBO J       Date:  2009-03-19       Impact factor: 11.598

6.  Expression of IL-1β in rhesus EAE and MS lesions is mainly induced in the CNS itself.

Authors:  Saskia Maria Burm; Laura Anna Norma Peferoen; Ella Alwine Zuiderwijk-Sick; Krista Geraldine Haanstra; Bert Adriaan 't Hart; Paul van der Valk; Sandra Amor; Jan Bauer; Jeffrey John Bajramovic
Journal:  J Neuroinflammation       Date:  2016-06-06       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.